Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Conestoga suffered relative underperformance in 2025 due to a speculative, 'low-quality' small-cap rally and a massive biotech surge. However, the manager is highly constructive heading into 2026 due to robust earnings growth forecasts and attractive valuation discounts for Small Caps.
Full Quick Take
Conestoga suffered relative underperformance in 2025 due to a speculative, 'low-quality' small-cap rally and a massive biotech surge. However, the manager is highly constructive heading into 2026 due to robust earnings growth forecasts and attractive valuation discounts for Small Caps.
